{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T08:21:14Z","timestamp":1782375674809,"version":"3.54.5"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.lungcan.2020.11.007","type":"journal-article","created":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T11:52:26Z","timestamp":1605700346000},"page":"16-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Thyroid dysfunction in non-small cell lung cancer patients treated with epidermal growth factor receptor and anaplastic lymphoma kinase inhibitors: Results of a prospective cohort"],"prefix":"10.1016","volume":"151","author":[{"given":"Swati","family":"Soni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashu","family":"Rastogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuruswamy T.","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Digambar","family":"Behera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navneet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.lungcan.2020.11.007_bib0005","doi-asserted-by":"crossref","first-page":"R91","DOI":"10.1530\/EJE-14-0198","article-title":"Endocrine side-effects of anti-cancer drugs: thyroid effects of tyrosine kinase inhibitors","volume":"171","author":"Illouz","year":"2014","journal-title":"Eur. J. Endocrinol."},{"issue":"5","key":"10.1016\/j.lungcan.2020.11.007_bib0010","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.4158\/EP11182.CR","article-title":"Erlotinib-associated exacerbation of hypothyroidism with pericardial tamponade","volume":"18","author":"Kastoon","year":"2012","journal-title":"Endocr. Pract."},{"issue":"9","key":"10.1016\/j.lungcan.2020.11.007_bib0015","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1200\/JCO.2017.76.7293","volume":"36","author":"Kalemkerian","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2020.11.007_bib0020","doi-asserted-by":"crossref","first-page":"257","DOI":"10.4103\/0970-2113.180801","volume":"33","author":"Maturu","year":"2016","journal-title":"Lung India"},{"issue":"3","key":"10.1016\/j.lungcan.2020.11.007_bib0025","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cllc.2015.10.002","article-title":"Comorbidity assessment using charlson comorbidity index and simplified comorbidity score and its association with clinical outcomes during first-line chemotherapy for lung Cancer","volume":"17","author":"Singh","year":"2016","journal-title":"Clin. Lung Cancer"},{"issue":"4","key":"10.1016\/j.lungcan.2020.11.007_bib0030","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1089\/thy.2017.0579","article-title":"Risk factors for new hypothyroidism during tyrosine kinase inhibitor therapy in advanced nonthyroidal cancer patients","volume":"28","author":"Lechner","year":"2018","journal-title":"Thyroid"},{"issue":"11","key":"10.1016\/j.lungcan.2020.11.007_bib0035","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1089\/thy.2010.0251","article-title":"Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia","volume":"20","author":"Kim","year":"2010","journal-title":"Thyroid"},{"issue":"2","key":"10.1016\/j.lungcan.2020.11.007_bib0040","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/annonc\/mdm483","article-title":"Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib","volume":"19","author":"Tamaskar","year":"2008","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2020.11.007_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2020.100570","article-title":"Clinical predictors of response to EGFR-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer: a real-world multicentric cohort analysis from India","volume":"44","author":"Garg","year":"2020","journal-title":"Curr. Probl. Cancer"},{"issue":"3","key":"10.1016\/j.lungcan.2020.11.007_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2020.100571","article-title":"Real world experience of treatment and outcome in ALK-rearranged metastatic nonsmall cell lung cancer: a multicenter study from India","volume":"44","author":"Patel","year":"2020","journal-title":"Curr. Probl. Cancer"},{"issue":"3","key":"10.1016\/j.lungcan.2020.11.007_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2020.100591","article-title":"Lung cancer in India: the rewards of REWERDS (REal world evidence from retrospective data analysiS)","volume":"44","author":"Singh","year":"2020","journal-title":"Curr. Probl. Cancer"},{"issue":"6","key":"10.1016\/j.lungcan.2020.11.007_bib0060","first-page":"723","article-title":"Thyroid dysfunctions induced by tyrosine kinase inhibitors","volume":"13","author":"Fallahi","year":"2014","journal-title":"Expert Opin. Drug Saf."},{"issue":"8","key":"10.1016\/j.lungcan.2020.11.007_bib0065","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11864-020-00768-2","article-title":"Immunotherapy alone or in combination with chemotherapy as first-line treatment of non-small cell lung Cancer","volume":"21","author":"Saxena","year":"2020","journal-title":"Curr. Treat. Options Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2020.11.007_bib0070","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1089\/thy.2013.0241","article-title":"Thyroid dysfunction as an unintended side effect of anticancer drugs","volume":"23","author":"Torino","year":"2013","journal-title":"Thyroid"},{"issue":"5","key":"10.1016\/j.lungcan.2020.11.007_bib0075","doi-asserted-by":"crossref","first-page":"405","DOI":"10.4103\/lungindia.lungindia_305_17","article-title":"Beyond epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) testing in advanced non-small cell lung cancer: is the picture as \"ROS1\" as it appears?","volume":"34","author":"Singh","year":"2017","journal-title":"Lung India"},{"key":"10.1016\/j.lungcan.2020.11.007_bib0080","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1200\/JGO.19.00357","article-title":"Unearthing EGFR mutations and the rewards of persistence in precision oncology: breaching the 10-year survival barrier in metastatic NSCLC with active disease","volume":"6","author":"Singh","year":"2020","journal-title":"JCO Glob Oncol"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220306826?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220306826?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:42:39Z","timestamp":1759236159000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500220306826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":16,"alternative-id":["S0169500220306826"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.11.007","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thyroid dysfunction in non-small cell lung cancer patients treated with epidermal growth factor receptor and anaplastic lymphoma kinase inhibitors: Results of a prospective cohort","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}